DCM
NAMS icon

DAFNA Capital Management’s NewAmsterdam Pharma NAMS Stock Holding History

DAFNA Capital Management’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,000
Closed -$640K – 93
2026
Q1 		$640K Buy
+20,000
New +$651K 0.15% 71

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

DAFNA Capital Management's NAMS Position: Q2 2026 in Review

DAFNA Capital Management sold out of NewAmsterdam Pharma (NAMS) in Q2 2026, closing a stake of 20,000 shares — an estimated $640K sold.

DAFNA Capital Management first reported a position in NAMS in Q1 2026 and held it in 1 quarter. The position peaked at $640K in Q1 2026. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • DAFNA Capital Management reported no remaining NewAmsterdam Pharma position as of Q2 2026 after selling out during the quarter.
  • DAFNA Capital Management sold 20,000 NewAmsterdam Pharma shares in Q2 2026, an estimated $640K.
  • DAFNA Capital Management first reported a position in NewAmsterdam Pharma in Q1 2026 and held it in 1 quarter.
  • DAFNA Capital Management's NewAmsterdam Pharma position peaked at $640K in Q1 2026.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.